INM
InMed Pharmaceuticals Inc (INM)
Healthcare • NASDAQ • $1.55+3.33%
- Symbol
- INM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $1.55
- Daily Change
- +3.33%
- Market Cap
- $4.94M
- Trailing P/E
- N/A
- Forward P/E
- -0.24
- 52W High
- $5.50
- 52W Low
- $0.58
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.97
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa…
Company websiteResearch INM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.